NL-OMON54782
Recruiting
Phase 4
Prevention of neuropsychiatric adverse effects caused by dexamethasone: insights from a placebo-controlled trial with hydrocortisone. - DEXA-CORT
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- eids Universitair Medisch Centrum
- Enrollment
- 180
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Cranial glioma, meningioma or brain metastasis scheduled to undergo surgery
- •(resection)
- •\- Minimal dose of peri\-operative cumulative dexamethasone of 24mg or more in 6
- •\- \>\=18 years
- •\- Good clinical condition; KPS\>\=70
- •\- Life expectancy \>\=6 months
Exclusion Criteria
- •\- Non\-native speakers of Dutch or insufficient command of the Dutch language
- •\- Patients that are unable to overview consequences of trial participation
- •\- Patients with severe aphasia
- •\- Patients that are not able to fill in the questionnaires because of cognitive
- •impairments at the discretion of the physician
- •\- Patients with psychiatric diseases or neurological deficits that interfere
- •with the study to the judgement of treating physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.europsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2017-003705-17-NLMC180
Completed
Not Applicable
Schizophrenia Termination Of Pharmacotherapy: STOP-trialSchizophrenia, schizophreniform disorder, schizoaffective disorderMental and Behavioural DisordersSchizophreniaISRCTN06332944The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)20
Suspended
Not Applicable
Schizophrenia Termination Of Pharmacotherapy-STOP-trial.Schizophrenic disorders:SchizophreniaSchizophreniform disorderSchizoaffective disorderNL-OMON26866Divisie Hersenen20
Recruiting
Not Applicable
Indicated prevention of mental disorders in subjects with initial panic symptomatology: effectiveness and underlying mechanisms of actioF00-F99Mental and behavioural disordersDRKS00018077Technische Universität Dresden, Institut für Klinische Psychologie und Psychotherapie, Professur Behaviorale Epidemiologie300
Completed
Not Applicable
Primary prevention of psychosis through interventions in the prodromal phaseISRCTN20328848Stavanger University Hospital (Norway)240